| Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ... Science immunology 6 (62), eabl4340, 2021 | 438 | 2021 |
| X-linked recessive TLR7 deficiency in~ 1% of men under 60 years old with life-threatening COVID-19 T Asano, B Boisson, F Onodi, D Matuozzo, M Moncada-Velez, ... Science immunology 6 (62), eabl4348, 2021 | 328 | 2021 |
| 2019 update of the drug resistance mutations in HIV-1 AM Wensing, V Calvez, F Ceccherini-Silberstein, C Charpentier, ... Topics in antiviral medicine 27 (3), 111, 2019 | 314 | 2019 |
| Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study J Gregson, M Tang, N Ndembi, RL Hamers, SY Rhee, VC Marconi, ... The Lancet infectious diseases 16 (5), 565-575, 2016 | 280 | 2016 |
| Zika virus in the female genital tract N Prisant, L Bujan, H Benichou, PH Hayot, L Pavili, S Lurel, C Herrmann, ... The Lancet infectious diseases 16 (9), 1000-1001, 2016 | 233 | 2016 |
| Hiv-2 molecular epidemiology B Visseaux, F Damond, S Matheron, D Descamps, C Charpentier Infection, Genetics and Evolution 46, 233-240, 2016 | 184 | 2016 |
| The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients E Teyssou, H Delagrèverie, B Visseaux, S Lambert-Niclot, S Brichler, ... The Journal of infection 83 (4), e1, 2021 | 172 | 2021 |
| Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients C Charpentier, T Nora, O Tenaillon, F Clavel, AJ Hance Journal of virology 80 (5), 2472-2482, 2006 | 152 | 2006 |
| Contribution of recombination to the evolution of human immunodeficiency viruses expressing resistance to antiretroviral treatment T Nora, C Charpentier, O Tenaillon, C Hoede, F Clavel, AJ Hance Journal of virology 81 (14), 7620-7628, 2007 | 149 | 2007 |
| Omicron SARS-CoV-2 variant: What we know and what we don’t VM Ferré, N Peiffer-Smadja, B Visseaux, D Descamps, J Ghosn, ... Anaesthesia, critical care & pain medicine 41 (1), 100998, 2022 | 131 | 2022 |
| The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies J Manry, P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, ... Proceedings of the National Academy of Sciences 119 (21), 2022 | 127 | 2022 |
| Detection of monkeypox virus in anorectal swabs from asymptomatic men who have sex with men in a sexually transmitted infection screening program in Paris, France VM Ferré, A Bachelard, M Zaidi, L Armand-Lefevre, D Descamps, ... Annals of internal medicine 175 (10), 1491-1492, 2022 | 123 | 2022 |
| Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors C Charpentier, DE Dwyer, F Mammano, D Lecossier, F Clavel, AJ Hance Journal of virology 78 (8), 4234-4247, 2004 | 116 | 2004 |
| Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy* C Charpentier, M Karmochkine, D Laureillard, P Tisserand, L Belec, ... HIV medicine 9 (9), 765-770, 2008 | 115 | 2008 |
| Illegal gold miners in French Guiana: a neglected population with poor health M Douine, E Mosnier, Q Le Hingrat, C Charpentier, F Corlin, L Hureau, ... BMC public health 18, 1-10, 2018 | 101 | 2018 |
| Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL) V Joly, C Burdet, R Landman, M Vigan, C Charpentier, C Katlama, ... Journal of Antimicrobial Chemotherapy 74 (3), 739-745, 2019 | 98 | 2019 |
| Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study P Recordon-Pinson, C Soulié, P Flandre, D Descamps, M Lazrek, ... Antimicrobial agents and chemotherapy 54 (8), 3335-3340, 2010 | 93 | 2010 |
| Mutations located outside the integrase gene can confer resistance to HIV-1 integrase strand transfer inhibitors I Malet, F Subra, C Charpentier, G Collin, D Descamps, V Calvez, ... MBio 8 (5), 10.1128/mbio. 00922-17, 2017 | 82 | 2017 |
| Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients S Fourati, C Charpentier, C Amiel, L Morand-Joubert, S Reigadas, ... Journal of Antimicrobial Chemotherapy 70 (5), 1507-1512, 2015 | 77 | 2015 |
| Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in … D Descamps, ML Chaix, B Montes, S Pakianather, C Charpentier, A Storto, ... Journal of antimicrobial chemotherapy 65 (12), 2620-2627, 2010 | 77 | 2010 |
